| Application Number | Priority Date | Filing Date | Title | 
|---|---|---|---|
| DK840870X | 1957-08-03 | 
| Publication Number | Publication Date | 
|---|---|
| GB840870Atrue GB840870A (en) | 1960-07-13 | 
| Application Number | Title | Priority Date | Filing Date | 
|---|---|---|---|
| GB22705/58AExpiredGB840870A (en) | 1957-08-03 | 1958-07-15 | Improvements in or relating to insulin preparations | 
| Country | Link | 
|---|---|
| CY (1) | CY217A (en) | 
| GB (1) | GB840870A (en) | 
| MY (1) | MY6100048A (en) | 
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| WO2014118355A1 (en) | 2013-02-04 | 2014-08-07 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| WO2015104311A1 (en)* | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| US9526764B2 (en) | 2008-10-17 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1-agonist | 
| US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine | 
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin | 
| US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| US9895423B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart | 
| US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation | 
| US9981013B2 (en) | 2010-08-30 | 2018-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the treatment of diabetes mellitus type 2 | 
| US9987332B2 (en) | 2011-09-01 | 2018-06-05 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease | 
| US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine | 
| US10159713B2 (en) | 2015-03-18 | 2018-12-25 | Sanofi-Aventis Deutschland Gmbh | Treatment of type 2 diabetes mellitus patients | 
| US10434147B2 (en) | 2015-03-13 | 2019-10-08 | Sanofi-Aventis Deutschland Gmbh | Treatment type 2 diabetes mellitus patients | 
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US10117909B2 (en) | 2008-10-17 | 2018-11-06 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1 agonist | 
| US9526764B2 (en) | 2008-10-17 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a GLP-1-agonist | 
| US12303598B2 (en) | 2009-11-13 | 2025-05-20 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1-agonist and methionine | 
| US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine | 
| US10029011B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine | 
| US10028910B2 (en) | 2009-11-13 | 2018-07-24 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1-agonist and methionine | 
| US9981013B2 (en) | 2010-08-30 | 2018-05-29 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the treatment of diabetes mellitus type 2 | 
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin | 
| US9987332B2 (en) | 2011-09-01 | 2018-06-05 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease | 
| EP3747426A1 (en) | 2013-02-04 | 2020-12-09 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| WO2014118355A1 (en) | 2013-02-04 | 2014-08-07 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| US9839675B2 (en) | 2013-02-04 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| US9895423B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart | 
| CN105899191A (en)* | 2014-01-09 | 2016-08-24 | 赛诺菲 | Stabilized glycerol-free pharmaceutical preparations of insulin analogues and/or insulin derivatives | 
| US10610595B2 (en) | 2014-01-09 | 2020-04-07 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| CN105899191B (en)* | 2014-01-09 | 2020-06-16 | 赛诺菲 | Stabilized glycerol-free pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| WO2015104311A1 (en)* | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives | 
| US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation | 
| US12186374B2 (en) | 2014-12-12 | 2025-01-07 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation | 
| US10434147B2 (en) | 2015-03-13 | 2019-10-08 | Sanofi-Aventis Deutschland Gmbh | Treatment type 2 diabetes mellitus patients | 
| US10159713B2 (en) | 2015-03-18 | 2018-12-25 | Sanofi-Aventis Deutschland Gmbh | Treatment of type 2 diabetes mellitus patients | 
| Publication number | Publication date | 
|---|---|
| MY6100048A (en) | 1961-12-31 | 
| CY217A (en) | 1961-03-27 | 
| Publication | Publication Date | Title | 
|---|---|---|
| GB840870A (en) | Improvements in or relating to insulin preparations | |
| GB1214733A (en) | A method for the preparation of stannous salt/palladium compositions | |
| Kinsky et al. | Neurospora nitrate reductase: The role of phosphate, flavine and cytochrome c reductase | |
| GB1463966A (en) | Depilatory formulation | |
| ES263099A2 (en) | Stabilized galactomannan gum solutions and process | |
| GB1160314A (en) | Acidified Hydrogen Peroxide Solutions for Dissolving Metals | |
| JPS5642970A (en) | Redox battery | |
| GB718574A (en) | Bath for the deposit of gold alloys by electroplating | |
| GB1038678A (en) | Compounds having an adrenocorticotrophic hormone action and process for their manufacture | |
| GB907303A (en) | Improvements in or relating to the production of semi-conductor devices | |
| GB1310610A (en) | Electro-less nickel plating compositions | |
| Jaffe et al. | Studies on prolactin inhibition of thyroxine-induced metamorphosis in Rana catesbeiana tadpoles | |
| GB835638A (en) | Insulin crystal suspensions having a protracted effect | |
| US2695860A (en) | Stabilized pteroyl solutions | |
| GB1247980A (en) | Copper alloy cleaning process | |
| GB748857A (en) | Process for the making of adrenocorticotrophin (acth) preparations having a prolonged action from acth with high specific activity | |
| GB889769A (en) | Slowly acting insulin preparation in crystalline form | |
| GB1488807A (en) | Agents for the selective combating of weeds | |
| GB929220A (en) | Gold plating | |
| ES464642A1 (en) | Preparations of 3-n-pyrrolidino-4-phenoxy-5-sulphamyl-benzolc acid and process for their manufacture | |
| GB594355A (en) | Improvements in or relating to silver solder alloys | |
| GB709927A (en) | Improved process for producing insulin preparations with protracted effect | |
| GB1386584A (en) | Method of preparation of purine sugar derivatives | |
| GB1492106A (en) | Gelatine dessert composition | |
| GB708888A (en) | Improved process for producing injectable insulin preparations with protracted effect |